Proofreading Enzyme Structure Revealed: A Leap Toward Potent COVID‑19 Antivirals

Proofreading Enzyme Structure Sheds Light on Antiviral Design

The first atomic‑resolution view of the SARS‑CoV‑2 proofreading enzyme has been published, offering a template for next‑generation nucleotide analogs. Researchers used cryo‑EM to freeze the exoribonuclease in multiple conformations, revealing how it excises mis‑incorporated bases. These insights explain why many existing antivirals falter – the enzyme spots and removes faulty nucleotides before they become part of the viral genome. A ↑ 85% boost in inhibitor binding affinity was recorded when compounds were redesigned to fit the newly mapped pocket.

“Targeting the exonuclease could finally close the loophole that lets the virus evade treatment,” said a lead virologist.

The study, highlighted by Reuters, suggests that tailoring drugs to evade the proofreading enzyme may restore potency to a class of medicines previously deemed ineffective. Parallel work cited by Bloomberg is already testing modified nucleotides that slip past the exonuclease’s grip. As the scientific community races to outpace viral evolution, the findings also intersect with broader nuclear research on high‑resolution structural techniques.

Dispatch from Dr. Silas Mercer (Biotech & Longevity Editor).